Peplin, Inc. company is developing drugs aimed at treating potentially cancerous skin conditions. Its lead drug candidate, a topical gel, is intended to serve as a less-costly alternative to surgical treatments for a common pre-cancerous skin condition known as actinic keratosis (AK). Derived from a plant known as petty spurge or radium weed, the product will be used to treat AK (characterized by rough patches of skin resulting from excessive exposure to sunlight) before it develops into skin cancer. Peplin was acquired by pharmaceutical giant LEO Pharma in late 2009 for $285 million.

ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the United States Food and Drug Administration (FDA), for chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. On January 27, 2009, Nuvelo, Inc. (Nuvelo) completed the merger with ARCA biopharma, Inc. (ABI). Pursuant to the Merger, Dawn Acquisition Sub, Inc. merged with and into ABI, with ABI continuing after the merger as the surviving company and a wholly owned subsidiary of Nuvelo. Pursuant to the Merger, ABI changed its name to ARCA biopharma Colorado, Inc. and Nuvelo changed its name to ARCA biopharma, Inc.

Roche Diagnostics Corporation company was founded in 1998 and is headquartered in Indianapolis, Indiana. Roche Diagnostics Corporation operates as a subsidiary of Roche Holding AG. Roche Diagnostics Corporation offers diagnostic tests and systems. The company operates in the diagnostic areas of diabetes care, centralized diagnostics, applied science, molecular diagnostics, and point-of-care diagnostics. Its products include diagnostics tools that test for congestive heart failure, HIV, Hepatitis B and C, fertility, and diabetes diseases. The company supplies its products to researchers, physicians, patients, hospitals, and laboratories. It has facilities in Indiana, New Jersey, South Carolina, Colorado, New Hampshire, Puerto Rico, and California, as well as locations in Canada.

Prolexys Pharmaceuticals wouldn't necessarily characterize proteins as difficult to characterize, especially not if it's using the technology it developed. The biotech research firm's HySpec and HyNet are high-throughput systems for protein expression, purification, and analysis. Prolexys, formerly known as Myriad Proteomics, has also developed its own bioinformatics to put together protein interaction maps from the data generated by HySpec and HyNet. The company has been focusing on cancer research, working with groups such as Columbia University and the Tower Cancer Research Foundation to study advanced solid tumors. Myriad Genetics spun off Prolexys, which was founded in 2001, as a private company in 2003.

Fluidigm Corporation was founded as Mycometrix Corporation in 1999 and changed its name to Fluidigm Corporation in June 2001. The company is based in San Francisco, California. Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis.

K-V Pharmaceutical Company (KV) is a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets branded and generic/non-branded prescription pharmaceutical products. The Company has a range of dosage form capabilities, including tablets, capsules, creams, liquids and ointments. KV conducts its branded pharmaceutical operations through Ther-Rx Corporation (Ther-Rx) and its generic/non-branded pharmaceutical operations through ETHEX Corporation (ETHEX). Through Particle Dynamics, Inc. (PDI), the Company also develops, manufactures and markets value-added raw material products for the pharmaceutical, nutritional, personal care, food and other markets. The Company has developed a variety of drug delivery and formulation technologies, which are primarily focused in four principal areas: SITE RELEASE; tastemasking; oral controlled release, and oral quick dissolving tablets.

Vermillion, Inc. is involved in the discovery, development and commercialization of diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company uses the process of utilizing advanced protein separation methods to identify and resolve variants of specific biomarkers (known as translational proteomics) for developing a procedure to measure a property or concentration of an analyte (known as an assay) and commercializing diagnostic tests. Vermillion has focuses in the areas of oncology, hematology, cardiology and women’s health. Vermillion’s focus on translational proteomics enables it to address the market for diagnostic tests that measure multiple protein biomarkers. In January 2010, the Company emerged from protection under Chapter 11 of the United States Bankruptcy Code.

Life Sciences Research stands ready to test everything that humans, animals, and the environment eat, use, and are exposed to. The contract research organization (CRO) performs safety and efficacy tests on pharmaceutical and chemical compounds used in products being developed by drug, agricultural, industrial, and veterinary companies. Life Sciences Research and its subsidiaries provide both large and start-up drugmaker clients worldwide with toxicology, metabolism, and stability studies for preclinical candidates that are applying for product approval. The company was taken private in 2009 after being acquired by Lion Holdings.

Bellus Health scientists are putting their gray matter to work to find therapies for incurable conditions. Formerly known as Neurochem, Bellus Health's lead candidate is a potential treatment for Amyloid A amyloidosis, an often fatal condition associated with inflammatory disease and kidney dysfunction. Bellus has licensed the late-stage compound to Centocor, which plans to market it under the name Kiacta. Bellus is also evaluating a potential treatment for type 2 diabetes in clinical trials and has discovery programs in the areas of Alzheimer's disease, diabetes, and metabolic syndrome. Its OVOS Natural Health business is touting homotaurine as a nutritional supplement to improve memory and cognition.

Launched in 1982 with a single product, Pharmadass (through subsidiary HealthAid) sells more than 450 products: vitamins and minerals, beauty care items, weight-loss formulas, and aromatherapy oils. It also sells anti-smoking products, herbal cigarettes, anti-snoring spray, and such supplements as fish oils and bee products. Specialty lines focus on such areas as mood enhancement, women's health, the immune system, and vitality. Pharmadass products are found in about 4,000 pharmacies and health food stores in the UK and in 30 countries worldwide.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.